Journal: Neuroscience letters

Article Title: Neural consequences of 5-Hz transcranial alternating current stimulation over right hemisphere: An eLORETA EEG study.

doi: 10.1016/j.neulet.2024.137849

Figure Lengend Snippet: Fig. 1. An illustration of the neuromodulation setup. Three electrode positions, namely F4, P4, and T8, were connected via wires to a rechargeable battery.

Article Snippet: We utilized Starstim-8, an FDA-approved neuromodulation device developed by Neuroelectrics, Inc., to treat anxiety disorders.

Techniques: Battery

Journal: npj Imaging

Article Title: Bridging preclinical and clinical fluorescence-guided surgery with advanced cancer vision goggles

doi: 10.1038/s44303-026-00170-x

Figure Lengend Snippet: Small animal fluorescence imaging systems ( a ) Pearl and ( b ) IVIS SpectrumCT equipped with enclosed, light-tight imaging chambers to minimize ambient light. c Advanced CVG platform for preclinical and clinical NIR cancer imaging. Cart-based clinical FGS systems ( d ) Quest Spectrum and ( e ) Stryker SPY-PHI equipped with a handheld camera/light tethered by power and network cords.

Article Snippet: To evaluate the performance of CVG fluorescence detection in the OR setting, we compared the CVG platform to the FDA-approved Stryker SPY-PHI handheld FGS device, imaging resected tumor tissues from patients undergoing head and neck cancer surgery (Fig. ).

Techniques: Fluorescence, Imaging

Journal: npj Imaging

Article Title: Bridging preclinical and clinical fluorescence-guided surgery with advanced cancer vision goggles

doi: 10.1038/s44303-026-00170-x

Figure Lengend Snippet: a Excitation and emission spectra of LS301 and preclinical FGS workflow (created with Biorender). b – e , Representative composite images showing pseudocolored NIR fluorescence overlaid on grayscale brightfield images of BALB/c mice ( n = 3) bearing subcutaneous 4T1 tumors ~24 h after intravenous injection of LS301-HSA (30 µM, 100 µL demonstrating FGS for tumor resection acquired with: ( b ) CVG – inset numbers indicate real-time quantitative fluorescence values at various signal thresholds; ( c ) Pearl – color scale [min = 4.70 × 10⁻², max = 3.22 × 10⁻¹]; ( d ) IVIS – color scale [min = 350, max = 2000]; ( e ) Quest Spectrum (Quest) – non-quantitative handheld imaging of dorsal flank regions. Panels from left to right show pre-surgery, exposed tumor after skin deflection, the post-resection, and after incision closure. Ex vivo imaging includes intact tumor (superficial—front; deep—back side), as well as 1.5-mm thick tumor slices. Tumor regions were delineated freehand based on fluorescence intensity and designated by dotted orange lines. f TNRs for CVG, Pearl, and IVIS were not significantly different, while CVG showed significantly higher TNR compared to Quest Spectrum ( P = 0.016). The red-circled area indicates the tumor ROI, while the white-circled area indicates the nontumor ROI in ( b – e ), which were selected for the TNR analysis. Data represent mean ± SD of TNRs from three mice. P values were calculated using one-way ANOVA with multiple comparisons in Prism 8.0.1. Scale bar: 5 mm.

Article Snippet: To evaluate the performance of CVG fluorescence detection in the OR setting, we compared the CVG platform to the FDA-approved Stryker SPY-PHI handheld FGS device, imaging resected tumor tissues from patients undergoing head and neck cancer surgery (Fig. ).

Techniques: Fluorescence, Injection, Imaging, Ex Vivo

Journal: npj Imaging

Article Title: Bridging preclinical and clinical fluorescence-guided surgery with advanced cancer vision goggles

doi: 10.1038/s44303-026-00170-x

Figure Lengend Snippet: a Representative visible-light image captured by CVG. b Pseudocolored NIR fluorescence overlay generated using a dynamic thresholding algorithm, overlaid on the visible image. The three boxed values represent fluorescence intensity thresholds for the top 10%, top 5%, and maximum intensity pixels. CVG images were acquired at a resolution of 480 × 640 (height × width) pixels from a fixed 50 cm working distance. c Visible image of the same tissue captured by the handheld Stryker SPY-PHI system (SPY-PHI). d NIR fluorescence (blue-to-red pseudocolor) overlaid on grayscale white-light image obtained by the Stryker SPY-PHI system in SPY-CSF mode. e Raw NIR fluorescence image from CVG. f , NIR fluorescence image obtained by the Stryker SPY-PHI system in SPY contrast mode. g Overlay of the top 15% fluorescence intensity pixels from the CVG NIR image (red) and the transformed Stryker SPY-PHI NIR image (green) in an RGB composite; yellow indicates overlapping regions. h Dice coefficient comparing the top 15% pixels from both systems: 0.84 ± 0.04 ( n = 6), with two outliers shown as brown dots (0.50 and 0.59). i Normalized intensity map (NIM) derived from the CVG NIR grayscale image, showing a mean of 19.84 ± 14.23 and a maximum of 54.93. j NIM from the transformed SPY-PHI image, with a mean of 2.76 ± 1.28 and a maximum of 4.77. Both NIMs were normalized by the mean intensity of the lowest 10% of pixels in the tissue sample. k Overlay of high-intensity NIM regions (NIM > 1.5) from CVG (red) and Stryker SPY-PHI (green) in RGB format, where yellow indicates overlap. l , Dice coefficient for NIM > 1.5 comparison: 0.91 ± 0.02 ( n = 6). Scale bars, 5 mm.

Article Snippet: To evaluate the performance of CVG fluorescence detection in the OR setting, we compared the CVG platform to the FDA-approved Stryker SPY-PHI handheld FGS device, imaging resected tumor tissues from patients undergoing head and neck cancer surgery (Fig. ).

Techniques: Fluorescence, Generated, Transformation Assay, Derivative Assay, Comparison

Journal: Frontiers in Neurology

Article Title: Cochlear implant electrode design for safe and effective treatment

doi: 10.3389/fneur.2024.1348439

Figure Lengend Snippet: Reports identified using the search terms on correlation between electrode angular insertion depth and hearing outcomes (references in Supplementary material S2 ).

Article Snippet: 9 , Selleck et al. (2019) , USA , All three FDA-approved CI devices , — , Positive.

Techniques: Variant Assay